Indivior stock gains as Supernus merger and special dividend plan come into focus

Published on 09/10/2026 at 16:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Indivior stock closed at USD 34.77 on Nasdaq on September 9, 2026, valuing the drug maker at about USD 4.10 billion. The planned merger with Supernus and a USD 1 billion special dividend are now key catalysts for investors.

Moderne Pharma-Produktionsanlage mit Glasfassade und Industrieanlagen im Tageslicht — Indivior PLC mit ISIN GB00BYZ0C031 betreibt moderne Pharma-Produktionsanlage für innovative Suchtmedizin-Präparate weltweit an Patienten, Illustration mit AI erstellt.

Indivior Pharmaceuticals, Inc. stock (ISIN GB00BYZ0C031) traded at USD 34.77 on the Nasdaq Global Select Market as of September 9, 2026, up 1.31% from the prior close of USD 34.32, giving the specialist drug manufacturer a market capitalization of about USD 4.10 billion.

Merger with Supernus and special dividend as main catalysts

The central strategic catalyst for Indivior stock is the planned all stock merger with Supernus Pharmaceuticals that is accompanied by a USD 1 billion special dividend to Indivior shareholders, a transaction detailed in an amended business combination registration statement filed with the U.S. Securities and Exchange Commission.

According to Stock Titan, the filing describes a USD 1.0 billion cash special dividend to be paid to Indivior shareholders in connection with the merger, which materially changes the company’s capital structure and is a core element of the equity story as of September 10, 2026.

As Stock Titan reports, the analysis supporting the merger indicated an implied per share equity value reference range for Indivior shares between USD 35.45 and USD 47.30, framing the transaction economics for investors who are now comparing that range to the current Nasdaq price of USD 34.77.

Price level, 52-week range and sector positioning

On a sector level, Indivior is classified in the Drug Manufacturers – Specialty and Generic grouping within healthcare and currently stands out as one of the larger names in that peer set.

Per a screener overview on Yahoo Finance, Indivior Pharmaceuticals, Inc. was quoted at USD 34.77 with a daily gain of 1.31% and a market capitalization of USD 4.104 billion, underlining its scale compared with other specialty and generic manufacturers as of September 9, 2026.

Within its trading history, the same screener data shows a 52-week low of USD 22.22 and a 52-week high of USD 42.81 for Indivior stock, meaning the current price of USD 34.77 sits about 56.5% above the 52-week low while remaining roughly 18.8% below the 52-week high, an intermediate positioning that reflects both the past rally and remaining upside potential relative to its own range.

Investor flows and analyst consensus

Beyond the merger and dividend story, investor positioning and analyst views also contribute to sentiment on Indivior stock in early September 2026.

According to a report on MarketBeat dated September 10, 2026, Virginia Retirement Systems and other institutional investors recently disclosed a combined USD 3.33 million investment in Indivior, highlighting ongoing institutional interest even as the company navigates a major corporate action.

The same MarketBeat overview states that six research analysts currently rate Indivior stock with a Buy rating and one assigns a Hold rating, leading to an average rating classified as Moderate Buy with a consensus price target of USD 45.17, which is about 29.9% above the latest Nasdaq close of USD 34.77.

For investors, that consensus target near USD 45.17 provides a numerical benchmark to measure both the merger valuation range described in SEC materials and the actual market price, especially as the special dividend and post-merger balance sheet could affect future earnings capacity and valuation multiples.

Corporate identity and recent transformation

Indivior has also undergone a notable corporate identity change that matters for stock investors tracking the ticker INDV.

Per company information summarized on Seeking Alpha, the company was formerly known as Indivior PLC and changed its name to Indivior Pharmaceuticals, Inc. in January 2026, reflecting its move to a U.S. corporate structure while maintaining its Nasdaq Global Select Market listing under the INDV ticker.

This transformation from a United Kingdom plc to a U.S. corporation sits alongside the planned merger with Supernus and the associated special dividend, collectively signaling a decisive strategic realignment toward the North American market and a more U.S.-centric investor base.

Stock price and market data snapshot

At the last completed trading day before publication, September 9, 2026, Indivior stock closed at USD 34.77 on the Nasdaq Global Select Market, up 1.31% from the prior close of USD 34.32, with trading around that level placing the shares between their 52-week low of USD 22.22 and high of USD 42.81 and underpinning a market capitalization of approximately USD 4.10 billion.